UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13A-16 OR15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Dated December 17, 2019
Commission File Number001-36421
AURINIA PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its charter)
N/A
(Translation of Registrant’s Name)
#1203-4464 Markham Street
Victoria, British Columbia
V8Z7X8
(250)708-4272
(Address and telephone number of registrant’s principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☐ Form40-F ☒
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☒ No ☐
This Form6-K is hereby filed and incorporated by reference into the Registrant’s Registration Statement on FormF-10 (FileNo. 333-222413).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: December 17, 2019 | Aurinia Pharmaceuticals Inc. | |||||||
By: | /s/ Peter S. Greenleaf | |||||||
Name: | Peter S. Greenleaf | |||||||
Title: | Chief Executive Officer |
EXHIBIT INDEX
Exhibit | Description of Exhibit | |
99.1 | Material Change Report, dated December 17, 2019 – Underwritten Public Offering |
Exhibit 99.1 included with this report on Form6-K is hereby incorporated by reference as an exhibit to the Registrant’s Registration Statement on FormF-10 (FileNo. 333-222413), as amended or supplemented.